Fig. 4
Cellular processes and pathways impacted by S1PR2. a Relative mRNA levels of S1PR2 in the RKO cancer cell line before and after overexpression (OE) of S1PR2. b In vivo tumor growth of S1PR2-overexpressing GFP-RKO (3 × 106) vs. scramble cells over 23 days after injection. c Cell cycle analysis on recovered RKO-derived tumors. d Relative mRNA levels of Axin2 in RKO cells. e Western blot analysis (left panel) and densitometry (right panel) analysis of total (AKT) and phosphorylated AKT (p-AKT) in RKO cells. f mRNA (right panel) and protein (right panel) levels of PTEN. g Western blot (left panel) and densitometry (right panel) analysis of phosphorylated AKT (p-AKT) in the mucosa of AOM/DSS treated S1PR2−/− and S1PR2+/+ mice. mRNA is mean ± SEM, normalized to the expression of GAPDH and expressed as 2-ΔCt. The significance was evaluated by the Mann-Witney test, whereas the cell cycle by one-way ANOVA followed by Bonferroni’s test; *p < 0.05; ** p < 0.01. Data are representative of 2 independent experiments; n = 4